Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8937534 | 1.00 | LMNA (0.57) | LMNAALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8937543 | 1.00 | LMNA (0.57) | LMNAALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8937452 | 0.96 | ALDH1A1 (0.62) | LMNAALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8937573 | 0.93 | ALDH1A1 (0.64) | LMNAALDH1A1CYP2C19L3MBTL1KDM4E | |
| SCHEMBL8937243 | 0.91 | ALDH1A1 (0.58) | LMNAALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8937245 | 0.91 | ALDH1A1 (0.58) | LMNAALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8937247 | 0.91 | ALDH1A1 (0.58) | LMNAALDH1A1CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8937342 | 0.90 | ALDH1A1 (0.58) | LMNAALDH1A1CYP2C19L3MBTL1KDM4E | |
| SCHEMBL8937708 | 0.90 | ALDH1A1 (0.70) | LMNAALDH1A1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL8937338 | 0.90 | ALDH1A1 (0.58) | LMNAALDH1A1CYP2C19L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0395446-B1 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | SANKYO CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |